Biotech & Health

Gaithersburg-based Viela Bio Wins FDA Approval For Its First Drug

MBS Staff
Man conducting lab experiments

A spin-off from MedImmune — Viela Bio — one of the youngest biotechs in the region, now has its first FDA approval under its belt. It’s an enormous victory for any biotech where it can take decades to get FDA approval and a drug to market.

The company received approval from the Food and Drug Administration for Neuromyelitis Optica Spectrum Disorder (NMOSD), an autoimmune disorder that inflames and attacks the optic nerve, spinal cord and brain stem which could lead to blindness and paralysis.

Viela Bio has quickly grown to become one of the top five largest biotechs in the Washington D.C. area measured by market value.

Disqus Comments